Loading
Life sciences · Journal article
International Journal of Molecular Sciences · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cancer immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies (BsAbs), and immune checkpoint inhibitors (ICIs), have improved outcomes across hematologic and solid malignancies. Infection risk remains heterogeneous and depends on treatment platform, target antigen, lymphodepletion, immune reconstitution, concomitant immunosuppression, and supportive care. This narrative review synthesizes clinical trials, observational studies, and guidance identified through PubMed/MEDLINE, reference screening, and a targeted literature update through October 2026. It focuses on infection incidence, microbiological spectrum, antimicrobial resistance (AMR), multidrug-resistant (MDR) colonization and infection, antimicrobial exposure, prevention, and stewardship. Severe infections can be frequent with BCMA-directed BsAbs: the MagnetisMM-3 study reported grade 3–4 infections in 39.8% of elranatamab-treated patients, while a pooled global teclistamab cohort reported grade 3–4 infections in 55.3%; these estimates are study-specific and are influenced in part by COVID-19. Direct AMR evidence is concentrated in CAR-T and broader cellular-therapy cohorts, while comparable data for BsAbs and ICIs remain limited. Associations between broad-spectrum antibiotic exposure, microbiome disruption, and CAR-T outcomes are clinically important but remain vulnerable to confounding. Prevention should integrate immune status, prior microbiology, antimicrobial exposure, and local resistance patterns rather than infer resistance risk from treatment platform alone. Prospective studies using harmonized outcomes are needed to improve individualized infection prevention and antimicrobial stewardship.